个人中心 - 老虎社区

Tygerniu1

IP属地：未知

帖子 · 14帖子 · 14
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Tygerniu1Tygerniu1
  ·2021-12-16
  Wow
  46 Biggest Movers From Yesterday
  Gainers Theseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday. CMC Materials,
  46 Biggest Movers From Yesterday
  1,019 2
  3
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-28
  Good
  Cathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M
  Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth
  Cathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M
  688 3
  5
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-25
  $XIAOMI-W(01810)$Xiao mi has good home appliances
  949 1
  2
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-25
  Go tesla
  Cathie Wood’s ARK Innovation turns positive for the year as growth stocks surge
  After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positi
  Cathie Wood’s ARK Innovation turns positive for the year as growth stocks surge
  526 评论
  2
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-24
  Good stock
  536 评论
  1
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-24
  Buy
  Activist investor who shook up Bed Bath & Beyond and Kohl's says this is the next big retail opportunity
  Macellum Capital Management CEO Jonathan Duskin has two very successful, high-profile activist campa
  Activist investor who shook up Bed Bath & Beyond and Kohl's says this is the next big retail opportunity
  573 评论
  3
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-24
  Yes buy more
  非常抱歉，此主贴已删除
  564 评论
  5
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-22
  Rarrrr ascenda
  414 评论
  1
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-22
  Roarrrrrr
  These 3 Dow Stocks Are Set to Soar in 2021's Second Half
  Here are the companies investors are most excited about -- and why.
  These 3 Dow Stocks Are Set to Soar in 2021's Second Half
  487 评论
  6
  分享
  举报
- Tygerniu1Tygerniu1
  ·2021-06-21
  good news
  5 Ultra-Popular Stocks Wall Street Views as Overvalued
  If analysts are correct, these high-flying stocks will fizzle out over the next year.
  5 Ultra-Popular Stocks Wall Street Views as Overvalued
  519 2
  6
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4087275238029370","uuid":"4087275238029370","gmtCreate":1624172973859,"gmtModify":1624172973859,"name":"Tygerniu1","pinyin":"tygerniu1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":14,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.08","exceedPercentage":"60.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":690140681,"gmtCreate":1639649203437,"gmtModify":1639649205399,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/690140681","repostId":"1171817404","repostType":4,"repost":{"id":"1171817404","kind":"news","pubTimestamp":1639648605,"share":"https://ttm.financial/m/news/1171817404?lang=&edition=full","pubTime":"2021-12-16 17:56","market":"us","language":"en","title":"46 Biggest Movers From Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1171817404","media":"Benzinga","summary":"Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials,","content":"<p><b>Gainers</b></p>\n<ul>\n <li><b>Theseus Pharmaceuticals, Inc.</b>&nbsp;gained 34.1% to settle at $12.58 on Wednesday.</li>\n <li><b>CMC Materials, Inc.</b>&nbsp;climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.</li>\n <li><b>Biofrontera Inc.</b>&nbsp;shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.</li>\n <li><b>Regional Health Properties, Inc.</b>&nbsp;gained 23.8% to close at $6.70.Regional Health Props, last month, posted a Q3 loss of $1.25 per share.</li>\n <li><b>Gemini Therapeutics, Inc.</b>&nbsp;rose 23.1% to settle at $2.99 after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and a $20 price target.</li>\n <li><b>CN Energy Group. Inc.</b>&nbsp;jumped 22.4% to close at $3.01.</li>\n <li><b>Mesoblast Limited</b>&nbsp;climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.</li>\n <li><b>Broadstone Acquisition Corp.</b>&nbsp;gained 19.1% to close at $10.68.</li>\n <li><b>Cabaletta Bio, Inc.</b>&nbsp;jumped 18.2% to settle at $3.97.</li>\n <li><b>Ensysce Biosciences, Inc.</b>&nbsp;surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.</li>\n <li><b>Trio-Tech International</b>&nbsp;gained 16.6% to close at $9.42.</li>\n <li><b>Aerovate Therapeutics, Inc.</b>&nbsp;jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.</li>\n <li><b>Optical Cable Corporation</b>&nbsp;gained 16.2% to settle at $6.40.</li>\n <li><b>Conn's, Inc.</b>&nbsp;rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.</li>\n <li><b>Design Therapeutics, Inc.</b>&nbsp;surged 16% to settle at $20.36.</li>\n <li><b>Bird Global, Inc.</b>&nbsp;gained 15.7% to close at $8.97.</li>\n <li><b>VerifyMe, Inc.</b>&nbsp;jumped 13.7% to close at $3.65.</li>\n <li><b>East Stone Acquisition Corporation</b>&nbsp;gained 12.9% to close at $15.24 after declining 26% on Tuesday.</li>\n <li><b>Vir Biotechnology, Inc.</b>&nbsp;gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.</li>\n <li><b>SeaChange International, Inc.</b>&nbsp;rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.</li>\n <li><b>Nxt-ID, Inc.</b>&nbsp;shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.</li>\n <li><b>Tandem Diabetes Care, Inc.</b>&nbsp;climbed 10.5% to close at $144.34.</li>\n <li><b>Eli Lilly and Company</b>&nbsp;climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.</li>\n <li><b>Borr Drilling Limited</b>&nbsp;gained 9.2% to close at $1.67 after declining over 4% on Tuesday..</li>\n <li><b>Galera Therapeutics, Inc.</b>&nbsp;gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.</li>\n</ul>\n<p><b>Losers</b></p>\n<ul>\n <li><b>Atai Life Sciences N.V.</b>&nbsp;dropped 31.9% to close at $6.82 on Wednesday.</li>\n <li><b>China Xiangtai Food Co., Ltd.</b>&nbsp;fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.</li>\n <li><b>Aspen Group, Inc.</b>&nbsp;shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.</li>\n <li><b>REV Group, Inc.</b>&nbsp;fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.</li>\n <li><b>Idera Pharmaceuticals, Inc.</b>&nbsp;shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.</li>\n <li><b>LianBio</b>&nbsp;fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.</li>\n <li><b>The Oncology Institute, Inc.</b>&nbsp;fell 17.9% to close at $6.25.</li>\n <li><b>Alzamend Neuro, Inc.</b>&nbsp;fell 15.9% to close at $2.59 after jumping 28% on Tuesday.</li>\n <li><b>LogicBio Therapeutics, Inc</b>&nbsp;dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.</li>\n <li><b>Legend Biotech Corporation</b>&nbsp;shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.</li>\n <li><b>Huadi International Group Co., Ltd.</b>&nbsp;fell 15% to close at $27.62.</li>\n <li><b>iSpecimen Inc.</b>&nbsp;fell 13.3% to close at $10.87.</li>\n <li><b>MIND Technology, Inc.</b>&nbsp;shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.</li>\n <li><b>Adagio Therapeutics, Inc.</b>&nbsp;fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.</li>\n <li><b>Zai Lab Limited</b>&nbsp;fell 12.4% to close at $54.90.</li>\n <li><b>Cerence Inc.</b>&nbsp;dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.</li>\n <li><b>ABM Industries Incorporated</b>&nbsp;fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.</li>\n <li><b>BeiGene, Ltd.</b>&nbsp;fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.</li>\n <li><b>Cooper-Standard Holdings Inc.</b>&nbsp;fell 7.1% to close at $19.71.</li>\n <li><b>Nisun International Enterprise Development Group Co., Ltd</b>&nbsp;fell 6.9% to close at $3.50.</li>\n <li><b>I-Mab</b>&nbsp;fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>46 Biggest Movers From Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n46 Biggest Movers From Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 17:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials, Inc. climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired...</p>\n\n<a href=\"https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171817404","content_text":"Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials, Inc. climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.\nBiofrontera Inc. shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.\nRegional Health Properties, Inc. gained 23.8% to close at $6.70.Regional Health Props, last month, posted a Q3 loss of $1.25 per share.\nGemini Therapeutics, Inc. rose 23.1% to settle at $2.99 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target.\nCN Energy Group. Inc. jumped 22.4% to close at $3.01.\nMesoblast Limited climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.\nBroadstone Acquisition Corp. gained 19.1% to close at $10.68.\nCabaletta Bio, Inc. jumped 18.2% to settle at $3.97.\nEnsysce Biosciences, Inc. surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.\nTrio-Tech International gained 16.6% to close at $9.42.\nAerovate Therapeutics, Inc. jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.\nOptical Cable Corporation gained 16.2% to settle at $6.40.\nConn's, Inc. rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.\nDesign Therapeutics, Inc. surged 16% to settle at $20.36.\nBird Global, Inc. gained 15.7% to close at $8.97.\nVerifyMe, Inc. jumped 13.7% to close at $3.65.\nEast Stone Acquisition Corporation gained 12.9% to close at $15.24 after declining 26% on Tuesday.\nVir Biotechnology, Inc. gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.\nSeaChange International, Inc. rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.\nNxt-ID, Inc. shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.\nTandem Diabetes Care, Inc. climbed 10.5% to close at $144.34.\nEli Lilly and Company climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.\nBorr Drilling Limited gained 9.2% to close at $1.67 after declining over 4% on Tuesday..\nGalera Therapeutics, Inc. gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.\n\nLosers\n\nAtai Life Sciences N.V. dropped 31.9% to close at $6.82 on Wednesday.\nChina Xiangtai Food Co., Ltd. fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.\nAspen Group, Inc. shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.\nREV Group, Inc. fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.\nIdera Pharmaceuticals, Inc. shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.\nLianBio fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.\nThe Oncology Institute, Inc. fell 17.9% to close at $6.25.\nAlzamend Neuro, Inc. fell 15.9% to close at $2.59 after jumping 28% on Tuesday.\nLogicBio Therapeutics, Inc dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.\nLegend Biotech Corporation shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.\nHuadi International Group Co., Ltd. fell 15% to close at $27.62.\niSpecimen Inc. fell 13.3% to close at $10.87.\nMIND Technology, Inc. shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.\nAdagio Therapeutics, Inc. fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.\nZai Lab Limited fell 12.4% to close at $54.90.\nCerence Inc. dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.\nABM Industries Incorporated fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.\nBeiGene, Ltd. fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.\nCooper-Standard Holdings Inc. fell 7.1% to close at $19.71.\nNisun International Enterprise Development Group Co., Ltd fell 6.9% to close at $3.50.\nI-Mab fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.","news_type":1,"symbols_score_info":{"BGNE":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":1019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":127433112,"gmtCreate":1624861704836,"gmtModify":1631889497788,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/127433112","repostId":"1110515408","repostType":4,"repost":{"id":"1110515408","kind":"news","pubTimestamp":1624859565,"share":"https://ttm.financial/m/news/1110515408?lang=&edition=full","pubTime":"2021-06-28 13:52","market":"us","language":"en","title":"Cathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M","url":"https://stock-news.laohu8.com/highlight/detail?id=1110515408","media":"Benzinga","summary":"Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth","content":"<p>Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth about $9.55 million, in&nbsp;<b>UiPath Inc</b>(NYSE:PATH).</p>\n<p>Shares of the New York-based software automation company closed 1.04% higher at $69.77 on Friday.</p>\n<p>The investment firm made the purchase via&nbsp;the&nbsp;<b>ArkGenomic Revolution ETF</b>(BATS:ARKG).</p>\n<p>Ark owns PATH shares via all of its six active ETFs. On a consolidated basis, the Wood-led firm now holds over 10 million shares, worth around $670 million in UiPath.</p>\n<p>The products of the Bucharest, Romania-based&nbsp;software companyare used by organizations to help efficiently automate their various business processes. PATH closed 5.34% higher on Wednesday, giving the company a market valuation of $35.8 billion.</p>\n<p>Some of the other key Ark Invest sells on Friday include&nbsp;<b>Pluristem Therapeutics</b>(NASDAQ:PSTI) and buys include&nbsp;<b>Quantum-Si Inc</b>(NASDAQ:QSI).</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 13:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/long-ideas/21/06/21737470/cathie-wood-buys-another-9-6m-in-uipath-raises-stake-in-automation-company-to-670m><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth about $9.55 million, in UiPath Inc(NYSE:PATH).\nShares of the New York-based software automation ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21737470/cathie-wood-buys-another-9-6m-in-uipath-raises-stake-in-automation-company-to-670m\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21737470/cathie-wood-buys-another-9-6m-in-uipath-raises-stake-in-automation-company-to-670m","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110515408","content_text":"Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth about $9.55 million, in UiPath Inc(NYSE:PATH).\nShares of the New York-based software automation company closed 1.04% higher at $69.77 on Friday.\nThe investment firm made the purchase via the ArkGenomic Revolution ETF(BATS:ARKG).\nArk owns PATH shares via all of its six active ETFs. On a consolidated basis, the Wood-led firm now holds over 10 million shares, worth around $670 million in UiPath.\nThe products of the Bucharest, Romania-based software companyare used by organizations to help efficiently automate their various business processes. PATH closed 5.34% higher on Wednesday, giving the company a market valuation of $35.8 billion.\nSome of the other key Ark Invest sells on Friday include Pluristem Therapeutics(NASDAQ:PSTI) and buys include Quantum-Si Inc(NASDAQ:QSI).","news_type":1,"symbols_score_info":{"PATH":0.9,"PSTI":0.9,"QSI":0.9}},"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126476077,"gmtCreate":1624583210999,"gmtModify":1631889497803,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>Xiao mi has good home appliances","listText":"<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>Xiao mi has good home appliances","text":"$XIAOMI-W(01810)$Xiao mi has good home appliances","images":[{"img":"https://static.tigerbbs.com/4817f42d08f6512adb24db3e9ec64db5","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126476077","isVote":1,"tweetType":1,"viewCount":949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":126473799,"gmtCreate":1624583129111,"gmtModify":1631889497814,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Go tesla","listText":"Go tesla","text":"Go tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126473799","repostId":"1160571601","repostType":4,"repost":{"id":"1160571601","kind":"news","pubTimestamp":1624582048,"share":"https://ttm.financial/m/news/1160571601?lang=&edition=full","pubTime":"2021-06-25 08:47","market":"us","language":"en","title":"Cathie Wood’s ARK Innovation turns positive for the year as growth stocks surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1160571601","media":"CNBC","summary":"After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positi","content":"<div>\n<p>After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positive for the year as investors begin to give growth names a nod.\nThe actively managed ETF rose 1.5% on...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Innovation turns positive for the year as growth stocks surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Innovation turns positive for the year as growth stocks surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positive for the year as investors begin to give growth names a nod.\nThe actively managed ETF rose 1.5% on...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","TDOC":"Teladoc Health Inc.","SHOP":"Shopify Inc"},"source_url":"https://www.cnbc.com/2021/06/24/cathie-woods-ark-innovation-turns-positive-for-the-year.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1160571601","content_text":"After a tumultuous first half of 2021, Cathie Wood’s flagship fund —ARK Innovation— just went positive for the year as investors begin to give growth names a nod.\nThe actively managed ETF rose 1.5% on Thursday, bringing its year-to-date gain to just shy of 1%. The innovation fund has rallied 5.4% this week and over 11% this month.\nSince bottoming on May 13 — a day after thehottest inflation reading since 2008— the fund is up about 25%.\n\nARK Innovation started to suffer in late February when a striking rotation from growth to value occurred in the market. However, fears of higher interest rates triggered by inflation appear overblown, as the U.S. 10-year Treasury sits around 1.5% after hitting a high near 1.8% at the end of March.\nWith interest rates continuing to come down and the threat of inflation under control, investors are now shifting back to their favorite growth names, and Wood’s Ark Invest is back on an upswing.\nWood called the comeback earlier this month. She told clients“the rotation back to growth is probably close at hand”on June 8.\nWood’s theory is that consumer spending is going to make a major move to the services sector after dominating in the goods sector during the coronavirus pandemic. Wood presciently said this would spur a decline in commodity prices and cyclical stocks, setting the stage for outperformance in innovation names.\nTo be sure, the fund has a long way to go to breach its record high from February. The ETF sits about 21% from its 52-week high.\nPower in ARK’s top holdings\nWood — known for taking advantage of dips in her highest conviction picks — spent the last few volatile months doubling down on her top holdings. Recently, Wood — a longtime bitcoin bull — has taken advantage of weakness inDraftKings,CoinbaseandGrayscale Bitcoin Trust.\n“We have capitalized on this volatility by selling names that have held up better than others and moving into names ... those that we have a high degree of conviction and those that are more opportunistic,” shesaid during an ARK webinarthis month. Wood told CNBC last month she now expects a 25% annual rate of return in her top holdings over the next five years.\nSince April’s hot inflation report released on May 12, Wood’s top holdings bottomed out and have led the ETF higher.\nCNBC Pro arranged the fund’s holding based on market valuation and screened for how much the equities have gained since then.\nShares of Tesla— the fund’s largest holding — are up roughly 15% since mid-May as of Wednesday’s close.\nAs of Wednesday’s close,Teladoc Health and Shopify are up about 20% and 43%, respectively, since the May bottom.Squarehas gained 21% andZoom Videohas popped 30% since then.TwilioandUnity Softwareare up 37% and 40% since the May bottom, respectively. DocuSign is up a whopping 52% in that time.\nWood made a name for herself after a banner 2020 where ARK Innovation returned nearly 150%.\nARK Innovation has seen roughly $7 billion of investor money enter the ETF in 2021, according to FactSet. In the past year, the $15 billion in fund flows have rushed Wood’s flagship fund.","news_type":1,"symbols_score_info":{"SHOP":0.9,"TDOC":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128942171,"gmtCreate":1624499559393,"gmtModify":1631889497827,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Good stock","listText":"Good stock","text":"Good stock","images":[{"img":"https://static.tigerbbs.com/7f03dc57da51443e95e6f2b7898a268b","width":"1125","height":"2412"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128942171","isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128949288,"gmtCreate":1624499325844,"gmtModify":1631889497837,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128949288","repostId":"2145801329","repostType":4,"repost":{"id":"2145801329","kind":"news","pubTimestamp":1624498951,"share":"https://ttm.financial/m/news/2145801329?lang=&edition=full","pubTime":"2021-06-24 09:42","market":"us","language":"en","title":"Activist investor who shook up Bed Bath & Beyond and Kohl's says this is the next big retail opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2145801329","media":"Yahoo Finance","summary":"Macellum Capital Management CEO Jonathan Duskin has two very successful, high-profile activist campa","content":"<p>Macellum Capital Management CEO Jonathan Duskin has two very successful, high-profile activist campaigns in the retail space under his belt, and is now shifting his gaze specifically to the underperforming apparel sector in a bid to find potential money-making opportunities.</p>\n<p>\"The market is entering a period of prosperity for traditional apparel retailers. The time has come when we will see apparel retailers consistently beat [number]s and be revalued higher,\" Duskin wrote in a note obtained by Yahoo Finance. \"In summary, the Amazon / [e-commerce] threat has been met, discretionary spending is set to accelerate with a meaningful tailwind, spending is shifting away from the home, the significant capital expenditure and SG&amp;A spending cycle is over and having stores has suddenly become an offensive weapon. The result will drive earnings and cash flow significantly higher than 2019 and we believe the group will be accorded higher multiples as long-term visibility improves.\"</p>\n<p>Duskin told Yahoo Finance Live the apparel sector has several other positive catalysts lurking, including consumers rebuilding their closets and the kicking in of the child tax credit come the key back to school shopping season.</p>\n<p>To be sure, Duskin has a solid case that many apparel stocks may be undervalued relative to their future earnings potential on the other side of the pandemic.</p>\n<p>The <a href=\"https://laohu8.com/S/IBUY\">Amplify Online Retail ETF</a> — which tracks the performance of apparel brands such as Lands' End and Stitch Fix —is only up 11.8% year-to-date. As for the S&amp;P Retailing Index it's up 12.6% this year. The S&amp;P 500 has notched a 13% gain so far this year.</p>\n<p>Meanwhile, a casual look at price-earnings multiples (PE) in the apparel space underscore Duskin's point.</p>\n<p>For instance, shares of apparel retailers Abercrombie &amp; Fitch, Gap, American Eagle Outfitters, <a href=\"https://laohu8.com/S/PVH\">PVH Corp</a>. and Polo Ralph Lauren all trade at relative discounts to the S&amp;P 500 on a forward price-to-earnings multiple basis. The average discount for these five stocks compared to the S&amp;P 500 from a P/E perspective is about 22%, according to data compiled by Yahoo Finance.</p>\n<p>'We think it's a unique time for retailers, particularly apparel retailers. There is a lot of dynamics that will favor them, much like we saw coming out of the Great Recession. I think apparel retailers are poised to outperform over the next two to four years for a host of reasons. Inventories are low. They learned to do more with less during COVID-19. Stores are now a weapon,\" explained Duskin.</p>\n<p>Duskin's missive follows a successful activist campaign at struggling Kohl's in April. As part of a settlement with Macellum, Ancora Holdings, Legion Partners Asset Management and 4010 Capital Kohl's added three new members to its board. It also expanded its stock buyback plan to $2 billion.</p>\n<p>The activist says he is searching for new targets. He continues to hold shares of Kohl's.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Activist investor who shook up Bed Bath & Beyond and Kohl's says this is the next big retail opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActivist investor who shook up Bed Bath & Beyond and Kohl's says this is the next big retail opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 09:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/activist-investor-who-shook-up-bed-bath-beyond-and-kohls-says-this-is-the-next-big-retail-opportunity-190331054.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Macellum Capital Management CEO Jonathan Duskin has two very successful, high-profile activist campaigns in the retail space under his belt, and is now shifting his gaze specifically to the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/activist-investor-who-shook-up-bed-bath-beyond-and-kohls-says-this-is-the-next-big-retail-opportunity-190331054.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FL":"富乐客","DKS":"迪克体育用品","UAA":"安德玛公司A类股","KSS":"柯尔百货","UA":"安德玛公司C类股","GCO":"格涅斯科","NKE":"耐克","PVH":"PVH Corp","WMT":"沃尔玛","TGT":"塔吉特","AMZN":"亚马逊","RL":"拉夫劳伦","BBBY":"3B家居","M":"梅西百货","LE":"Lands End Inc","SFIX":"Stitch Fix Inc.","ANF":"爱芬奇","EXPR":"Express, Inc."},"source_url":"https://finance.yahoo.com/news/activist-investor-who-shook-up-bed-bath-beyond-and-kohls-says-this-is-the-next-big-retail-opportunity-190331054.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145801329","content_text":"Macellum Capital Management CEO Jonathan Duskin has two very successful, high-profile activist campaigns in the retail space under his belt, and is now shifting his gaze specifically to the underperforming apparel sector in a bid to find potential money-making opportunities.\n\"The market is entering a period of prosperity for traditional apparel retailers. The time has come when we will see apparel retailers consistently beat [number]s and be revalued higher,\" Duskin wrote in a note obtained by Yahoo Finance. \"In summary, the Amazon / [e-commerce] threat has been met, discretionary spending is set to accelerate with a meaningful tailwind, spending is shifting away from the home, the significant capital expenditure and SG&A spending cycle is over and having stores has suddenly become an offensive weapon. The result will drive earnings and cash flow significantly higher than 2019 and we believe the group will be accorded higher multiples as long-term visibility improves.\"\nDuskin told Yahoo Finance Live the apparel sector has several other positive catalysts lurking, including consumers rebuilding their closets and the kicking in of the child tax credit come the key back to school shopping season.\nTo be sure, Duskin has a solid case that many apparel stocks may be undervalued relative to their future earnings potential on the other side of the pandemic.\nThe Amplify Online Retail ETF — which tracks the performance of apparel brands such as Lands' End and Stitch Fix —is only up 11.8% year-to-date. As for the S&P Retailing Index it's up 12.6% this year. The S&P 500 has notched a 13% gain so far this year.\nMeanwhile, a casual look at price-earnings multiples (PE) in the apparel space underscore Duskin's point.\nFor instance, shares of apparel retailers Abercrombie & Fitch, Gap, American Eagle Outfitters, PVH Corp. and Polo Ralph Lauren all trade at relative discounts to the S&P 500 on a forward price-to-earnings multiple basis. The average discount for these five stocks compared to the S&P 500 from a P/E perspective is about 22%, according to data compiled by Yahoo Finance.\n'We think it's a unique time for retailers, particularly apparel retailers. There is a lot of dynamics that will favor them, much like we saw coming out of the Great Recession. I think apparel retailers are poised to outperform over the next two to four years for a host of reasons. Inventories are low. They learned to do more with less during COVID-19. Stores are now a weapon,\" explained Duskin.\nDuskin's missive follows a successful activist campaign at struggling Kohl's in April. As part of a settlement with Macellum, Ancora Holdings, Legion Partners Asset Management and 4010 Capital Kohl's added three new members to its board. It also expanded its stock buyback plan to $2 billion.\nThe activist says he is searching for new targets. He continues to hold shares of Kohl's.","news_type":1,"symbols_score_info":{"AMZN":0.9,"ANF":0.9,"BBBY":0.9,"DKS":0.9,"EXPR":0.9,"FL":0.9,"GCO":0.9,"KSS":0.9,"LE":0.9,"M":0.9,"NKE":0.9,"PVH":0.9,"RL":0.9,"SFIX":0.9,"TGT":0.9,"UA":0.9,"UAA":0.9,"WMT":0.9}},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128940639,"gmtCreate":1624499284421,"gmtModify":1631889497849,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Yes buy more","listText":"Yes buy more","text":"Yes buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128940639","repostId":"2145156570","repostType":4,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129247677,"gmtCreate":1624375451199,"gmtModify":1631889497862,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Rarrrr ascenda&nbsp;","listText":"Rarrrr ascenda&nbsp;","text":"Rarrrr ascenda","images":[{"img":"https://static.tigerbbs.com/2a8606d61cac7d858060f586fe6024cd","width":"1125","height":"2412"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129247677","isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129245597,"gmtCreate":1624375373519,"gmtModify":1631889497873,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"Roarrrrrr","listText":"Roarrrrrr","text":"Roarrrrrr","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129245597","repostId":"2145056554","repostType":4,"repost":{"id":"2145056554","kind":"highlight","pubTimestamp":1624356900,"share":"https://ttm.financial/m/news/2145056554?lang=&edition=full","pubTime":"2021-06-22 18:15","market":"us","language":"en","title":"These 3 Dow Stocks Are Set to Soar in 2021's Second Half","url":"https://stock-news.laohu8.com/highlight/detail?id=2145056554","media":"Motley Fool","summary":"Here are the companies investors are most excited about -- and why.","content":"<p>The <b>Dow Jones Industrial Average </b>(DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past years. But given everything that's happening in the economy, it's not surprising to see investors rein in their expectations somewhat on some of the top-performing stocks in the market.</p>\n<p>Yet even with the gains the overall market has seen, there are still some Dow stocks that haven't climbed as far as they might. In particular, analysts looking at three stocks among the Dow Jones Industrials see the potential for substantial gains in the second half of 2021 and beyond. Below, we'll look at these three companies to see what it'll take for them to produce the big returns that investors want right now.</p>\n<h3>UnitedHealth: 34% upside</h3>\n<p><b>UnitedHealth Group </b>(NYSE:UNH) has already put in a reasonable performance in the Dow so far this year. The health insurance giant's stock is up about 11% year to date, outpacing the broader average very slightly.</p>\n<p>Yet investors see a lot more upside for the healthcare giant. The top price target among Wall Street analysts for UnitedHealth is $522 per share, which implies roughly a 34% gain from current levels.</p>\n<p>UnitedHealth has done an excellent job of navigating the ever-changing landscape of the healthcare and health insurance industries. As the largest health insurance company in the world, UnitedHealth offers coverage not just for private businesses but also for those eligible for government programs like Medicare and Medicaid.</p>\n<p>Indeed, UnitedHealth's handling of plans under the Affordable Care Act has been masterful, with the company having participated in the program better known as Obamacare while not overcommitting to it. With the Supreme Court having recently upheld the validity of the Affordable Care Act, UnitedHealth finds itself in a strong position to keep benefiting from its mix of business.</p>\n<p><img src=\"https://static.tigerbbs.com/ffe66b7aafd67e07dd42007f2b60d638\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Yet many overlook the value of UnitedHealth's Optum health services unit. By aiming to help providers encourage health and wellness, Optum generates higher-margin revenue while often producing better outcomes for patients and members. With both growth drivers pushing the company forward, UnitedHealth looks well poised to keep climbing.</p>\n<h3>Goldman Sachs: 36% upside</h3>\n<p>Wall Street has enjoyed the bull market in stocks, and that's been a blessing for investment bank <b>Goldman Sachs </b>(NYSE:GS). The perennial financial giant has seen its stock rise 34% so far in 2021 after less impressive performance during 2020.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, Goldman has reflected the broader performance of financial stocks across the market. Interest rates have generally been on the rise, and that's bolstered the prospects for more net-interest income from retail banking operations. Goldman lags behind its big-bank peers on the consumer banking front, but its relatively new Marcus unit has done a good job of attracting capital thus far.</p>\n<p>On the other hand, Goldman continues to rely on its investment banking operations, and strong activity levels among initial public offerings and mergers and acquisitions (M&amp;A) have fed the company's coffers nicely. Financing remains relatively easy to get, and that could spur more M&amp;A activity that in turn could keep growing revenue for Goldman's investment banking division. Add to that possible tailwinds from macroeconomic factors, and it is in a solid position to climb as high as the $484 per share that represents the top price target among those following the financial stock.</p>\n<h3>Apple: 42% upside</h3>\n<p>Lastly, <b>Apple </b>(NASDAQ:AAPL) rounds out this list. Recently fetching $130 per share, some see the iPhone maker's stock climbing to $185. That'd be a 42% jump to help Apple recover from its 2% loss so far in 2021.</p>\n<p>Apple's gains have continued to impress. Revenue jumped 54% in its most recent quarter, with sales of the iPhone 12 and various other products and accessories continuing to drive sales for the company. Returning capital to shareholders via dividends and stock buybacks has had a substantial impact on financial performance, especially with the number of outstanding shares having plunged by roughly 35% in just the past decade.</p>\n<p>Many fear that Apple hasn't generated the innovative product lines that drove its success in the mid-2000s. However, at least for now, consumers seem content with iterations on existing product lines, and as long as that remains a successful strategy, further gains for the stock seem realistic.</p>\n<h3>Further to run?</h3>\n<p>Even with solid gains for the Dow in 2021, the long-term trajectory for stocks remains upward. That's a big part of why Apple, Goldman Sachs, and UnitedHealth Group look as promising as they do. Smart investors should at least keep an eye on these three stocks to see if they can live up to their full potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 Dow Stocks Are Set to Soar in 2021's Second Half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 Dow Stocks Are Set to Soar in 2021's Second Half\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 18:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Dow Jones Industrial Average (DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","GS":"高盛","AAPL":"苹果","UNH":"联合健康","09086":"华夏纳指-U"},"source_url":"https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145056554","content_text":"The Dow Jones Industrial Average (DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past years. But given everything that's happening in the economy, it's not surprising to see investors rein in their expectations somewhat on some of the top-performing stocks in the market.\nYet even with the gains the overall market has seen, there are still some Dow stocks that haven't climbed as far as they might. In particular, analysts looking at three stocks among the Dow Jones Industrials see the potential for substantial gains in the second half of 2021 and beyond. Below, we'll look at these three companies to see what it'll take for them to produce the big returns that investors want right now.\nUnitedHealth: 34% upside\nUnitedHealth Group (NYSE:UNH) has already put in a reasonable performance in the Dow so far this year. The health insurance giant's stock is up about 11% year to date, outpacing the broader average very slightly.\nYet investors see a lot more upside for the healthcare giant. The top price target among Wall Street analysts for UnitedHealth is $522 per share, which implies roughly a 34% gain from current levels.\nUnitedHealth has done an excellent job of navigating the ever-changing landscape of the healthcare and health insurance industries. As the largest health insurance company in the world, UnitedHealth offers coverage not just for private businesses but also for those eligible for government programs like Medicare and Medicaid.\nIndeed, UnitedHealth's handling of plans under the Affordable Care Act has been masterful, with the company having participated in the program better known as Obamacare while not overcommitting to it. With the Supreme Court having recently upheld the validity of the Affordable Care Act, UnitedHealth finds itself in a strong position to keep benefiting from its mix of business.\n\nImage source: Getty Images.\nYet many overlook the value of UnitedHealth's Optum health services unit. By aiming to help providers encourage health and wellness, Optum generates higher-margin revenue while often producing better outcomes for patients and members. With both growth drivers pushing the company forward, UnitedHealth looks well poised to keep climbing.\nGoldman Sachs: 36% upside\nWall Street has enjoyed the bull market in stocks, and that's been a blessing for investment bank Goldman Sachs (NYSE:GS). The perennial financial giant has seen its stock rise 34% so far in 2021 after less impressive performance during 2020.\nOn one hand, Goldman has reflected the broader performance of financial stocks across the market. Interest rates have generally been on the rise, and that's bolstered the prospects for more net-interest income from retail banking operations. Goldman lags behind its big-bank peers on the consumer banking front, but its relatively new Marcus unit has done a good job of attracting capital thus far.\nOn the other hand, Goldman continues to rely on its investment banking operations, and strong activity levels among initial public offerings and mergers and acquisitions (M&A) have fed the company's coffers nicely. Financing remains relatively easy to get, and that could spur more M&A activity that in turn could keep growing revenue for Goldman's investment banking division. Add to that possible tailwinds from macroeconomic factors, and it is in a solid position to climb as high as the $484 per share that represents the top price target among those following the financial stock.\nApple: 42% upside\nLastly, Apple (NASDAQ:AAPL) rounds out this list. Recently fetching $130 per share, some see the iPhone maker's stock climbing to $185. That'd be a 42% jump to help Apple recover from its 2% loss so far in 2021.\nApple's gains have continued to impress. Revenue jumped 54% in its most recent quarter, with sales of the iPhone 12 and various other products and accessories continuing to drive sales for the company. Returning capital to shareholders via dividends and stock buybacks has had a substantial impact on financial performance, especially with the number of outstanding shares having plunged by roughly 35% in just the past decade.\nMany fear that Apple hasn't generated the innovative product lines that drove its success in the mid-2000s. However, at least for now, consumers seem content with iterations on existing product lines, and as long as that remains a successful strategy, further gains for the stock seem realistic.\nFurther to run?\nEven with solid gains for the Dow in 2021, the long-term trajectory for stocks remains upward. That's a big part of why Apple, Goldman Sachs, and UnitedHealth Group look as promising as they do. Smart investors should at least keep an eye on these three stocks to see if they can live up to their full potential.","news_type":1,"symbols_score_info":{"03086":0.9,"09086":0.9,"AAPL":0.9,"GS":0.9,"UNH":0.9}},"isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120042160,"gmtCreate":1624289938350,"gmtModify":1631889497887,"author":{"id":"4087275238029370","authorId":"4087275238029370","name":"Tygerniu1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087275238029370","authorIdStr":"4087275238029370"},"themes":[],"htmlText":"good news","listText":"good news","text":"good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/120042160","repostId":"2145084835","repostType":4,"repost":{"id":"2145084835","kind":"highlight","pubTimestamp":1624280460,"share":"https://ttm.financial/m/news/2145084835?lang=&edition=full","pubTime":"2021-06-21 21:01","market":"us","language":"en","title":"5 Ultra-Popular Stocks Wall Street Views as Overvalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2145084835","media":"Motley Fool","summary":"If analysts are correct, these high-flying stocks will fizzle out over the next year.","content":"<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark <b>S&amp;P 500</b> since 1980, including dividends, is north of 11%.</p>\n<p>Not surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to <b>FactSet</b>, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.</p>\n<p>Based on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.</p>\n<p><img src=\"https://static.tigerbbs.com/b04ade705354c4825038c4dfcd0187d9\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Palantir Technologies: Implied downside of 12%</h3>\n<p>Since its direct listing in late September 2020, data-mining company <b>Palantir Technologies</b> (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's <a href=\"https://laohu8.com/S/AONE\">one</a>-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.</p>\n<p>The likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.</p>\n<p>Another possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.</p>\n<p>Over the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.</p>\n<p><img src=\"https://static.tigerbbs.com/a38605bee8e62f3e8aa414fa24278e7e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: Implied downside of 11%</h3>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.</p>\n<p>Why the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.</p>\n<p>The other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.</p>\n<p>Based solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.</p>\n<p><img src=\"https://static.tigerbbs.com/07841e6a8173146a0fbfddf95a0f1ccb\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>GameStop: Implied downside of 71%</h3>\n<p>This will probably come as a shock to no one, but Reddit favorite <b>GameStop</b> (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it <i>still</i> implies up to 71% downside over the next year.</p>\n<p>The biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.</p>\n<p>Although the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.</p>\n<p>With sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.</p>\n<p><img src=\"https://static.tigerbbs.com/c7ff785aa0040a5565d474390f58b47a\" tg-width=\"700\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Ocugen: Implied downside of 18%</h3>\n<p>Volatile clinical-stage biotech stock <b>Ocugen</b> (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.</p>\n<p>Arguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.</p>\n<p>What's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.</p>\n<p>Though it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.</p>\n<p><img src=\"https://static.tigerbbs.com/91f6037829ea3fb0ae1cae0b95d8d11e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>NVIDIA: Implied downside of 3%</h3>\n<p>Don't adjust your computer, laptop, or smartphone screens -- that really says <b>NVIDIA</b> (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.</p>\n<p>One reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.</p>\n<p>Perhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.</p>\n<p>For what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks Wall Street Views as Overvalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks Wall Street Views as Overvalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145084835","content_text":"Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark S&P 500 since 1980, including dividends, is north of 11%.\nNot surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to FactSet, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.\nBased on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.\n\nImage source: Getty Images.\nPalantir Technologies: Implied downside of 12%\nSince its direct listing in late September 2020, data-mining company Palantir Technologies (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's one-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.\nThe likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.\nAnother possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.\nOver the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.\n\nImage source: Getty Images.\nModerna: Implied downside of 11%\nBiotech stock Moderna (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's one of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.\nWhy the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.\nThe other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.\nBased solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.\n\nImage source: Getty Images.\nGameStop: Implied downside of 71%\nThis will probably come as a shock to no one, but Reddit favorite GameStop (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it still implies up to 71% downside over the next year.\nThe biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.\nAlthough the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.\nWith sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.\n\nImage source: Getty Images.\nOcugen: Implied downside of 18%\nVolatile clinical-stage biotech stock Ocugen (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.\nArguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.\nWhat's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.\nThough it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.\n\nImage source: Getty Images.\nNVIDIA: Implied downside of 3%\nDon't adjust your computer, laptop, or smartphone screens -- that really says NVIDIA (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.\nOne reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.\nPerhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.\nFor what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.","news_type":1,"symbols_score_info":{"GME":0.9,"MRNA":0.9,"NVDA":0.9,"OCGN":0.9,"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}